Table 2.
List of potential drugs for SARS-CoV-2 infection as identified by the L1000FWD analysis.
| Drug | Similarity score | P value | Q value | Z score | Combined score | Mode of action |
|---|---|---|---|---|---|---|
| BRD-K23875128 | −0.2717 | 3.53E-23 | 3.08E-20 | 1.82 | −40.95 | Rho kinase inhibitor |
| SA-792728 | −0.2391 | 3.53E-18 | 1.11E-15 | 1.75 | −30.61 | sphingosine kinase inhibitor |
| sirolimus | −0.2391 | 2.10E-18 | 7.19E-16 | 1.77 | −31.33 | MTOR inhibitor |
| BRD-K44366801 | −0.2283 | 4.53E-17 | 1.17E-14 | 1.75 | −28.62 | Unknown |
| TPCA-1 | −0.2174 | 5.15E-16 | 1.00E-13 | 1.8 | −27.53 | IKK inhibitor |
| selumetinib | −0.2174 | 6.28E-16 | 1.16E-13 | 1.77 | −26.83 | MEK inhibitor |
| ezetimibe | −0.2174 | 8.57E-16 | 1.53E-13 | 1.78 | −26.83 | Niemann-Pick C1-like 1 protein antagonist|Cholesterol inhibitor |
| desoximetasone | −0.2174 | 6.53E-16 | 1.20E-13 | 1.74 | −26.47 | Glucocorticoid receptor agonist |
| BRD-K60070073 | −0.2174 | 1.44E-16 | 3.26E-14 | 1.69 | −26.84 | Unknown |
| TPCA-1 | −0.2174 | 2.70E-16 | 5.72E-14 | 1.8 | −27.95 | IKK inhibitor |
| BRD-K03601405 | −0.2065 | 9.63E-16 | 1.69E-13 | 1.79 | −26.9 | Unknown |
| BRD-K88622704 | −0.2065 | 4.67E-15 | 7.02E-13 | 1.75 | −25.08 | Unknown |
| CT-200783 | −0.2065 | 1.73E-15 | 2.88E-13 | 1.82 | −26.92 | Unknown |
| CAM-9-027-3 | −0.2065 | 4.81E-16 | 9.49E-14 | 1.89 | −29.01 | Unknown |
| BRD-K25373946 | −0.1957 | 1.70E-14 | 2.28E-12 | 1.82 | −25.07 | Unknown |
| piperlongumine | −0.1957 | 4.30E-14 | 5.35E-12 | 1.79 | −23.92 | Unknown |
| BRD-K89687904 | −0.1957 | 3.43E-14 | 4.38E-12 | 1.79 | −24.07 | PKC inhibitor |
| NSC-632839 | −0.1957 | 9.94E-14 | 1.11E-11 | 1.65 | −21.47 | Ubiquitin specific protease inhibitor |
| BRD-K03371390 | −0.1957 | 7.20E-14 | 8.33E-12 | 1.77 | −23.28 | Unknown |
| BRD-K06765193 | −0.1957 | 3.18E-14 | 4.10E-12 | 1.73 | −23.39 | Unknown |
| BRD-K32101742 | −0.1957 | 7.46E-14 | 8.56E-12 | 1.67 | −21.95 | Unknown |
| WZ-4002 | −0.1848 | 1.25E-12 | 1.06E-10 | 1.64 | −19.48 | EGFR inhibitor |
| U-0126 | −0.1848 | 1.10E-12 | 9.46E-11 | 1.69 | −20.16 | MEK inhibitor |
| piperlongumine | −0.1848 | 2.30E-13 | 2.36E-11 | 1.84 | −23.29 | Unknown |
| radicicol | −0.1848 | 3.85E-13 | 3.78E-11 | 1.75 | −21.75 | HSP inhibitor |
| ABT-737 | −0.1848 | 3.40E-12 | 2.68E-10 | 1.73 | −19.88 | BCL inhibitor |
| arachidonyl-trifluoro-methane | −0.1848 | 2.67E-13 | 2.68E-11 | 1.86 | −23.43 | Cytosolic phospholipase inhibitor |
| fluticasone | −0.1848 | 6.79E-13 | 6.35E-11 | 1.81 | −22.07 | Glucocorticoid receptor agonist |
| BRD-K23875128 | −0.1848 | 1.53E-12 | 1.28E-10 | 1.78 | −21.02 | Rho kinase inhibitor |
| tyrphostin-AG-1296 | −0.1848 | 4.14E-13 | 4.02E-11 | 1.87 | −23.13 | FLT3 inhibitor |
| NVP-AUY922 | −0.1739 | 9.17E-12 | 6.31E-10 | 1.62 | −17.92 | HSP inhibitor |
| TPCA-1 | −0.1739 | 1.67E-11 | 1.05E-09 | 1.8 | −19.34 | IKK inhibitor |
| TPCA-1 | −0.1739 | 7.41E-13 | 6.81E-11 | 1.91 | −23.18 | IKK inhibitor |
| ST-4070169 | −0.1739 | 8.32E-12 | 5.84E-10 | 1.73 | −19.21 | Unknown |
| valdecoxib | −0.1739 | 1.67E-11 | 1.05E-09 | 1.78 | −19.18 | Cyclooxygenase inhibitor |
| EMF-bca1–16 | −0.1739 | 9.17E-12 | 6.31E-10 | 1.68 | −18.55 | Unknown |
| BIBU-1361 | −0.1739 | 7.06E-12 | 5.10E-10 | 1.82 | −20.29 | EGFR inhibitor |
| MD-II-038 | −0.1739 | 1.11E-11 | 7.37E-10 | 1.74 | −19.11 | Unknown |
| methoxsalen | −0.1739 | 1.48E-11 | 9.49E-10 | 1.79 | −19.39 | DNA synthesis inhibitor |
| MK-2206 | −0.1739 | 8.88E-12 | 6.18E-10 | 1.8 | −19.91 | AKT inhibitor |
| TPCA-1 | −0.1739 | 1.11E-11 | 7.37E-10 | 1.83 | −20.02 | IKK inhibitor |
| phenethyl-isothiocyanate | −0.1739 | 8.06E-12 | 5.69E-10 | 1.82 | −20.21 | Antineoplastic |
| BRD-A09984573 | −0.1739 | 8.32E-12 | 5.84E-10 | 1.71 | −18.98 | Unknown |
| BRD-K12244279 | −0.1739 | 9.79E-12 | 6.66E-10 | 1.69 | −18.64 | MEK inhibitor |
| PD-198306 | −0.163 | 8.94E-11 | 4.65E-09 | 1.7 | −17.04 | MEK inhibitor |
| BRD-K18726304 | −0.163 | 6.99E-11 | 3.76E-09 | 1.79 | −18.18 | Unknown |
| calmidazolium | −0.163 | 4.07E-11 | 2.36E-09 | 1.73 | −17.97 | Calmodulin antagonist |
| NSC-23766 | −0.163 | 7.44E-11 | 3.99E-09 | 1.79 | −18.15 | Rac GTPase inhibitor |
| BRD-K66037923 | −0.163 | 1.58E-10 | 7.51E-09 | 1.75 | −17.1 | Unknown |
| EMF-sumo1–11 | −0.163 | 2.87E-10 | 1.28E-08 | 1.65 | −15.78 | Unknown |